Deciphera Pharmaceuticals, Inc.
(NASDAQ : DCPH)

( )
DCPH After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 1.46%243.821.3%$802.48m
MRNAModerna, Inc. 6.60%69.470.0%$733.80m
IMMUImmunomedics, Inc. 0.07%85.3611.0%$689.62m
NVAXNovavax, Inc. 10.86%113.5696.5%$621.25m
GILDGilead Sciences, Inc. 0.00%62.251.0%$574.97m
ILMNIllumina, Inc. 4.74%299.893.5%$526.77m
REGNRegeneron Pharmaceuticals, Inc. 2.98%574.062.7%$437.73m
BIIBBiogen, Inc. 1.20%273.281.6%$337.14m
VRTXVertex Pharmaceuticals, Inc. 1.92%268.181.9%$334.55m
ALXNAlexion Pharmaceuticals, Inc. 2.15%114.432.0%$284.22m
SRNESorrento Therapeutics, Inc. 4.84%9.641.5%$258.41m
EXASEXACT Sciences Corp. 3.60%97.7020.7%$240.39m
VXRTVaxart, Inc. 7.40%7.400.0%$213.28m
SGENSeattle Genetics, Inc. 3.08%184.956.0%$210.15m
MNTAMomenta Pharmaceuticals, Inc. 0.02%52.403.0%$197.89m

Company Profile

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.